What Will Cardlytics Inc (NASDAQ: CDLX) Be Like In 2024

Cardlytics Inc (NASDAQ:CDLX) shares, rose in value, with the stock price down by -2.49% to the previous day’s close as strong demand from buyers drove the stock to $13.31.

Actively observing the price movement in the last trading, the stock closed the session at $13.65. The value of beta (5-year monthly) was 1.36. Referring to stock’s 52-week performance, its high was $20.52, and the low was $3.26. On the whole, CDLX has fluctuated by 73.53% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of Cardlytics Inc currently standing at about $587.10 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 14, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.12, which is expected to increase to $0.1 for fiscal year $0.1 and then to about $0.5 by fiscal year 2025. Data indicates that the EPS growth is expected to be 132.30% in 2025, while the next year’s EPS growth is forecast to be 400.00%.

Analysts have estimated the company’s revenue for the quarter at $71.69 million, with a low estimate of $70.99 million and a high estimate of $72.4 million. According to the average forecast, sales growth in current quarter could jump up 11.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $337.79 million, representing an increase of 9.20% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CDLX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CDLX currently trading nearly 9.81% and 47.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.40, while the 7-day volatility ratio is showing 9.04% which for the 30-day chart, stands at 11.71%. Furthermore, Cardlytics Inc (CDLX)’s beta value is 1.47, and its average true range (ATR) is 1.70.

A comparison of Cardlytics Inc (CDLX) with its peers suggests the former has fared considerably weaker in the market. CDLX showed an intraday change of -2.49% in last session, and over the past year, it grew by 292.05%%.

Data on historical trading for Cardlytics Inc (NASDAQ:CDLX) indicates that the trading volumes over the past 10 days have averaged 4.14 million and over the past 3 months, they’ve averaged 1.68 million. According to company’s latest data on outstanding shares, there are 44.11 million shares outstanding.

Nearly 7.59% of Cardlytics Inc’s shares belong to company insiders and institutional investors own 68.52% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.48 million shares as on Mar 15, 2024, resulting in a short ratio of 2.9. According to the data, the short interest in Cardlytics Inc (CDLX) stood at 10.16% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 4.15 million. The stock has risen by 44.52% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CDLX stock heading into the next quarter.